FoundationOne^®CDx Receives FDA-Approval as a Companion Diagnostic for ALUNBRIG^® (Brigatinib) to Identify Patients with ALK Positive Metastatic Non-Small Cell Lung Cancer

Foundation Medicine, Inc. announced that it has received approval from the US FDA for FoundationOne^®CDx to be used as a companion diagnostic for ALUNBRIG^®, which is currently FDA-approved for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.